Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Jun 24, 2014)
  • 8-K (May 12, 2014)
  • 8-K (May 8, 2014)
  • 8-K (Feb 19, 2014)
  • 8-K (Feb 14, 2014)
  • 8-K (Jan 30, 2014)

 
Other

Chelsea Therapeutics International 8-K 2012

Documents found in this filing:

  1. 8-K
  2. 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 12, 2012

 

  CHELSEA THERAPEUTICS INTERNATIONAL, LTD.  
  (Exact name of registrant as specified in its charter)  

 

 

Delaware 000-51462 20-3174202
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer ID Number)

 

3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277
(Address of principal executive offices)  (Zip Code)

 

Registrant’s telephone number, including area code (704) 341-1516

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

The 2012 annual meeting of stockholders for Chelsea Therapeutics International, Ltd. was held on June 12, 2012.

 

At the meeting, our stockholders elected seven members to our board of directors for a term expiring at the annual meeting of stockholders in 2013, as follows:

 

Members

 

Number of Shares

Voted For

Number of Shares

Against or Withheld (Includes Abstentions)

Broker Non-Votes
Simon Pedder   25,001,649 12,272,547 16,753,386
Kevan Clemens   24,715,463 12,558,733 16,753,386
Norman Hardman   33,544,136 3,730,060 16,753,386
Johnson Y.N. Lau   24,696,513 12,577,683 16,753,386
William D. Rueckert   37,002,672 271,524 16,753,386
Roger Stoll   24,717,673 12,556,523 16,753,386
Michael Weiser   33,553,502 3,720,694 16,753,386

 

At the meeting, our stockholders approved the advisory resolution approving the compensation of our named executive officers as presented in the Company’s proxy statement related to the annual meeting. The vote for such proposal was 23,935,610 shares for, 13,338,586 shares against (including abstentions) and 16,753,386 broker non-votes.

 

The stockholders also approved an amendment to the Chelsea Therapeutics International, Ltd. 2004 Stock Plan to increase the number of shares available for issuance under the plan by 3,000,000 shares, from 7,400,000 shares to 10,400,000 shares. The vote for such proposal was 23,754,032 shares for, 13,520,164 shares against (including abstentions) and 16,753,386 broker non-votes.

 

At the meeting, our stockholders also ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2012. The vote for such ratification was 53,540,061 shares for and 487,521 shares against (including abstentions).

 

 
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
     
     
     
Date:  June 12, 2012 /s/ J. Nick Riehle
  J. Nick Riehle, Chief Financial Officer

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki